Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor - LQFM030

A dynamic niching genetic algorithm strategy for docking highly flexible ligands

(2014) Camila Silva de Magalhães et al.   INFORMATION SCIENCES

Erratum: Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

A multiple minima genetic algorithm for protein structure prediction

(2013) Fábio Lima Custódio et al.   APPLIED SOFT COMPUTING

Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells

(2013) Hana Janouskova et al.   CANCER LETTERS

Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer

(2013) Tom Van Maerken et al.   CANCER LETTERS

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chemoselective and Regiospecific Formylation of 1-Phenyl-1H-pyrazoles Through the Duff Reaction

(2013) C. H. A. de Oliveira et al.   SYNTHETIC COMMUNICATIONS

Cellular Mechanisms Controlling Caspase Activation and Function

(2013) A. B. Parrish et al.   Cold Spring Harbor Perspectives in Biology

Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation

(2012) Eun Jung Park et al.   ANTI-CANCER DRUGS

Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells

(2012) Fengchun Ye et al.   CELL CYCLE

Structure–activity relationship and antitumor activity of thio-benzodiazepines as p53–MDM2 protein–protein interaction inhibitors

(2012) Zizhao Guo et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance inTP53wild-type ovarian cancer cells

(2012) Roser Mir et al.   INTERNATIONAL JOURNAL OF CANCER

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas

(2012) Angela M Sosin et al.   Journal of Hematology & Oncology

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas

(2012) A. Kunkele et al.   NEURO-ONCOLOGY

MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells

(2012) Sara Ghassemifar et al.   NEUROSCIENCE LETTERS

Avogadro: an advanced semantic chemical editor, visualization, and analysis platform

(2012) Marcus D Hanwell et al.   Journal of Cheminformatics

Mutations in the β-Tubulin Gene TUBB5 Cause Microcephaly with Structural Brain Abnormalities

(2012) Martin Breuss et al.   Cell Reports

The transcription-independent mitochondrial p53 program is a major contributor to Nutlin-induced apoptosis in tumor cells

(2011) Angelina V. Vaseva et al.   CELL CYCLE

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

(2011) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists

(2011) Hong Shen et al.   CURRENT PHARMACEUTICAL DESIGN

Recent Advances in the Therapeutic Perspectives of Nutlin-3

(2011) Paola Secchiero et al.   CURRENT PHARMACEUTICAL DESIGN

LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery

(2011) Roman A. Laskowski et al.   Journal of Chemical Information and Modeling

Investigation of Ehrlich ascites tumor cell death mechanisms induced by Synadenium umbellatum Pax.

(2011) Mariana Flavia da Mota et al.   JOURNAL OF ETHNOPHARMACOLOGY

Radiation-induced cell cycle arrests in Ehrlich ascites carcinoma cells in vivo

(2011) S. V. Tokalov et al.   RADIATION AND ENVIRONMENTAL BIOPHYSICS

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma

(2010) K. I. Pishas et al.   CLINICAL CANCER RESEARCH

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

(2009) Martin Enge et al.   CANCER CELL

Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells

(2009) M. Miyachi et al.   CLINICAL CANCER RESEARCH

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

(2009) Y. Tabe et al.   CLINICAL CANCER RESEARCH

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

(2009) Garrett M. Morris et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies

(2008) Paola Secchiero et al.   CURRENT PHARMACEUTICAL DESIGN

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Executioner caspase-3 and caspase-7 are functionally distinct proteases

(2008) J. G. Walsh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA